Last updated: July 31, 2026
Aminocaproic acid injection in plastic containers is a mature generic antifibrinolytic product with established FDA approval, limited active clinical-development activity, and minimal remaining composition-of-matter patent risk. Commercial demand is tied to hospital use in acute bleeding, perioperative blood conservation, trauma, obstetrics, urology, and selected hematology indications. The product’s principal risks are price competition, hospital purchasing consolidation, substitution by tranexamic acid, and manufacturing or supply interruptions rather than patent expiry.
What is aminocaproic acid injection in a plastic container?
Aminocaproic acid is a synthetic lysine analogue that inhibits fibrinolysis by blocking lysine-binding sites on plasminogen and reducing conversion of plasminogen to plasmin. The injectable product is used when rapid systemic antifibrinolytic treatment is required or when oral administration is impractical.
Common injectable presentations include:
| Product attribute |
Typical description |
| Active ingredient |
Aminocaproic acid |
| Dosage form |
Sterile intravenous injection |
| Common strength |
250 mg/mL |
| Common container |
Flexible plastic infusion container or plastic vial |
| Route |
Intravenous infusion or injection |
| Therapeutic class |
Antifibrinolytic |
| Primary use |
Reduction or prevention of excessive bleeding associated with hyperfibrinolysis |
| Regulatory status |
FDA-approved prescription drug; generic products marketed under ANDA pathways |
| Storage |
Product-specific; labeling generally requires controlled room-temperature storage |
The plastic container is a packaging and delivery configuration. It does not create a separate active ingredient, mechanism, or therapeutic category. The relevant intellectual-property issues are therefore associated with formulation, container-closure compatibility, manufacturing, and product-specific regulatory approvals rather than with a new chemical entity.
What is the FDA regulatory status of aminocaproic acid injection?
Aminocaproic acid is an established FDA-approved drug. The reference product, Amicar, has historically been marketed in oral and injectable forms. Generic manufacturers may obtain approval through abbreviated new drug applications when they demonstrate pharmaceutical equivalence, bioequivalence where applicable, and compliance with applicable quality requirements.
The injectable product is generally supplied for hospital and institutional use. FDA labeling identifies treatment of acute bleeding caused by elevated fibrinolytic activity, including conditions in which systemic antifibrinolysis is clinically appropriate.
Key regulatory points include:
- The product is a prescription drug.
- It is not a biologic and does not create a biosimilar pathway.
- Generic competition proceeds through the ANDA pathway rather than the 505(b)(2) pathway when the product qualifies as therapeutically equivalent to the reference product.
- The plastic container must satisfy container-closure, sterility, extractables and leachables, stability, and compatibility requirements.
- Injectable manufacturing is subject to current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211.
- Product labeling generally warns against use in patients with active intravascular clotting or disseminated intravascular coagulation unless appropriate management is provided.
The FDA’s Drugs@FDA and Orange Book databases should be used to confirm the current approval holder, therapeutic-equivalence code, and marketing status for each specific product presentation. Orange Book status can differ by manufacturer, strength, and package configuration. [1][2]
What clinical trials support aminocaproic acid?
The clinical evidence base is older and indication-specific. Aminocaproic acid is not supported by a modern, broad development program comparable to newer specialty drugs. Its use is based on historical controlled studies, clinical experience, regulatory labeling, and smaller perioperative or hematology studies.
Perioperative bleeding
Aminocaproic acid has been studied in cardiac surgery and other operations in which fibrinolysis contributes to blood loss. The clinical objective is reduction in perioperative bleeding and transfusion requirements. Use has declined in some institutions because tranexamic acid has become the preferred antifibrinolytic in many surgical protocols.
Hematology and mucosal bleeding
Aminocaproic acid remains relevant in patients with bleeding associated with dental procedures, oral mucosal injury, selected platelet disorders, and some inherited bleeding conditions. It can be used systemically or, in selected settings, as a local antifibrinolytic strategy.
Urology and urinary tract bleeding
The drug has historical use in urinary tract bleeding, but clot retention and obstruction are important clinical concerns. Use requires careful selection because suppression of fibrinolysis may stabilize clots in the urinary tract.
Obstetrics and gynecology
Aminocaproic acid has been used for selected obstetric and gynecologic bleeding scenarios. Tranexamic acid has stronger contemporary visibility in postpartum hemorrhage and is the preferred agent in many evidence-based protocols.
Trauma and emergency bleeding
Aminocaproic acid has been considered in trauma-related bleeding, but tranexamic acid dominates large-scale trauma evidence and guideline adoption. The CRASH-2 trial established a major evidence base for tranexamic acid, not aminocaproic acid. [3]
Current clinical-trial environment
The product has no evident late-stage clinical-trial program aimed at obtaining a new broad indication. Current research involving aminocaproic acid is more likely to be investigator-initiated, institutional, or comparative rather than sponsor-led registration research.
| Clinical area |
Evidence position |
Commercial effect |
| Cardiac surgery |
Established historical use; institutional protocols vary |
Supports recurring hospital demand |
| Dental and mucosal bleeding |
Continued niche use |
Supports outpatient and specialty demand |
| Hematology |
Useful in selected bleeding disorders |
Stable but limited volume |
| Trauma |
Limited relative to tranexamic acid |
Weak growth driver |
| Postpartum hemorrhage |
Competitor-led evidence base |
Tranexamic acid has strategic advantage |
| Urology |
Selective use with safety constraints |
Niche demand |
| New indications |
No major late-stage program |
Low probability of rapid expansion |
How many patents cover aminocaproic acid in plastic containers?
The original composition-of-matter protection for aminocaproic acid expired many years ago. The active ingredient is a mature generic compound, and no meaningful new-chemical-entity exclusivity remains.
The relevant protection categories are:
- Formulation patents.
- Container-closure or packaging patents.
- Manufacturing-process patents.
- Stability and compatibility claims.
- Method-of-use patents.
- Device or administration-system patents.
For a conventional aminocaproic acid injection in a plastic container, these categories generally create limited blocking risk. A manufacturer could still obtain or enforce a patent directed to a particular concentration, excipient system, container material, oxygen-control method, or manufacturing process. Such patents would not automatically block all aminocaproic acid injections.
Formulation patents
A simple aqueous injectable formulation containing aminocaproic acid and water for injection is difficult to protect broadly because the formulation is conventional and the active ingredient is old. Narrow claims may focus on:
- Specific pH ranges.
- Particular concentrations.
- Preservative-free configurations.
- Stability over defined storage periods.
- Low-particulate injectable formulations.
- Compatibility with a particular plastic polymer.
- Reduced degradation or impurity profiles.
The commercial value of these claims depends on whether they cover a necessary product attribute or merely an optional manufacturing design.
Plastic-container and manufacturing barriers
Plastic packaging can create technical risks involving:
- Drug adsorption to the container.
- Extractables and leachables.
- Permeation of oxygen or water vapor.
- Seal integrity.
- Container collapse during administration.
- Particulate generation.
- Compatibility with terminal sterilization or aseptic processing.
These are regulatory and operational barriers more often than durable market-exclusion tools. A competitor may avoid a packaging claim by using a different polymer, bottle, bag, port system, sterilization method, or filling process.
When does aminocaproic acid lose exclusivity?
Aminocaproic acid has already lost practical market exclusivity. The compound is available as a generic drug, and the main competitive question is not the date of a future small-molecule patent expiry. It is the number of approved suppliers and their ability to maintain reliable sterile manufacturing.
| Exclusivity category |
Current position |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired or commercially irrelevant |
| Orphan-drug exclusivity |
Not the principal protection framework |
| Pediatric exclusivity |
No material current barrier identified |
| Reference-product exclusivity |
Expired for the mature product |
| Formulation exclusivity |
Potentially narrow and product-specific |
| Method-of-use exclusivity |
Potentially narrow; generally does not block the generic molecule |
| Biosimilar exclusivity |
Not applicable |
Paragraph IV litigation is therefore unlikely to be the central market issue for conventional aminocaproic acid injection. A generic applicant would more commonly rely on the absence of unexpired blocking patents, a Paragraph III certification where applicable, or a product-specific certification strategy under the ANDA framework. The litigation profile is materially lower than for recently approved branded drugs with active Orange Book listings.
What is the Orange Book status of aminocaproic acid injection?
The Orange Book status must be assessed by specific product and sponsor. The reference-listed drug and generic versions may have different marketing statuses, package sizes, and therapeutic-equivalence listings.
For diligence purposes, the relevant checks are:
- Whether the product is listed as active or discontinued.
- Whether the product has an AB therapeutic-equivalence rating.
- Whether the plastic-container presentation is separately listed.
- Whether any patent information is listed for the reference product.
- Whether the approved manufacturer has an active commercial listing.
- Whether the product is subject to a shortage or supply alert.
A plastic container does not necessarily receive a separate Orange Book entry if it is only a package configuration of an already approved injectable product. The controlling issue is the FDA-approved application and the specific marketed presentation. [2]
Which companies are challenging aminocaproic acid’s market?
The market is primarily generic and supply-driven. Direct competition may come from generic manufacturers of aminocaproic acid injection, while indirect competition comes from other antifibrinolytics and blood-conservation products.
Direct competitors
Direct competitors include manufacturers that hold approved ANDAs or market aminocaproic acid injection under generic labeling. The supplier set can change because sterile injectable products are frequently discontinued, transferred, or temporarily unavailable.
Therapeutic competitors
The most important substitute is tranexamic acid. It has broader contemporary use in trauma, obstetrics, orthopedic surgery, cardiac surgery, and other bleeding settings. Aprotinin may be used in limited settings, subject to jurisdictional restrictions and institutional policies. Desmopressin, fibrinogen concentrates, prothrombin complex concentrates, topical thrombin, and blood-component strategies compete in selected clinical situations.
| Product |
Relative market position |
| Aminocaproic acid |
Mature generic; niche and institutional use |
| Tranexamic acid |
Primary antifibrinolytic competitor; stronger modern evidence base |
| Aprotinin |
Narrower use; regulatory availability varies |
| Desmopressin |
Different mechanism; selected bleeding disorders |
| Fibrinogen products |
Replacement therapy rather than direct antifibrinolysis |
| Topical hemostats |
Local alternatives in surgery |
What generic entry risks exist for aminocaproic acid injection?
Generic entry risk is already realized. Additional entrants can intensify pricing pressure, but sterile injectable markets do not always behave like high-volume oral generic markets. A limited number of qualified suppliers can support pricing stability when manufacturing capacity is constrained.
The principal risks are:
- New ANDA approvals increasing supplier count.
- Hospital group purchasing organization negotiations.
- Substitution by tranexamic acid.
- Tender-based price compression.
- Product discontinuation by low-margin suppliers.
- FDA manufacturing observations or warning letters.
- Raw-material shortages.
- Container or closure qualification failures.
- Recalls caused by sterility, particulate, or fill-volume issues.
The product’s competitive position is stronger when it is included in hospital protocols, stocked in emergency departments, or required by institutional formulary policy. It is weaker when hospitals use tranexamic acid as the default antifibrinolytic.
What is the market outlook for aminocaproic acid injection from 2025 to 2030?
Aminocaproic acid injection is a mature, low-growth hospital generic. The base case is stable-to-declining unit demand with periodic price volatility. Revenue can remain resilient if supply interruptions reduce the number of active suppliers, but long-term volume growth is unlikely without new evidence or guideline changes.
Indexed market projection
The following projection uses 2025 market revenue as an index of 100. It is a scenario model for the product category, not a reported company forecast.
| Year |
Downside case |
Base case |
Upside case |
| 2025 |
100 |
100 |
100 |
| 2026 |
94 |
99 |
104 |
| 2027 |
88 |
98 |
108 |
| 2028 |
82 |
97 |
112 |
| 2029 |
77 |
96 |
115 |
| 2030 |
72 |
95 |
118 |
Scenario assumptions
Downside case: Tranexamic acid adoption expands, aminocaproic acid loses formulary share, and additional generic suppliers reduce net pricing.
Base case: Hospital demand remains stable, with modest erosion from clinical substitution offset by periodic supply constraints.
Upside case: Shortages of competing antifibrinolytics, expanded institutional use, or renewed clinical interest in aminocaproic acid increases purchasing volume and average realized price.
The most likely commercial pattern is low single-digit annual unit erosion, partly offset by price increases during supply disruptions. Public company filings generally do not disclose aminocaproic acid revenue separately, so product-level revenue exposure must be estimated from portfolio data, institutional sales, procurement records, and shortage history.
How strong is the patent estate for aminocaproic acid in plastic containers?
The patent estate is weak as a broad exclusionary platform and moderate only for narrowly defined product or process claims. The active ingredient itself does not provide meaningful protection.
| Patent layer |
Strength |
Commercial relevance |
| Active ingredient |
Very weak |
No current exclusivity |
| Basic injectable formulation |
Weak |
Easily designed around if claims are narrow |
| Plastic-container configuration |
Low to moderate |
Relevant only if compatibility claims are specific |
| Manufacturing process |
Moderate if difficult to replicate |
May create operational advantage |
| Stability profile |
Low to moderate |
Can support regulatory differentiation |
| Method of use |
Narrow |
Usually indication-specific |
| Trade secrets and know-how |
Moderate |
Important in sterile manufacturing |
Manufacturing know-how may be more valuable than patent ownership. Reliable aseptic filling, container compatibility data, validated sterilization, and supply-chain controls can create a practical barrier even when the patent estate is thin.
What litigation and settlement activity affects the product?
No major current patent-litigation theme defines the conventional aminocaproic acid injection market. The product’s age and generic status reduce the likelihood of branded-style patent settlements delaying market entry.
The more relevant disputes are likely to involve:
- ANDA approval or product-specific regulatory issues.
- FDA inspection findings.
- Contract manufacturing agreements.
- Supply obligations.
- Product recalls.
- Hospital procurement contracts.
- Trademark or labeling matters.
- Patent claims directed to specialized formulations or packaging.
A Paragraph IV challenge would have limited strategic value unless a listed patent covered a commercially important, non-design-around presentation. For a conventional plastic-container injection, the absence of broad active-ingredient protection reduces the expected litigation value.
Does aminocaproic acid have biosimilar risk?
No. Aminocaproic acid is a synthetic small molecule, not a biologic. Biosimilar competition does not apply. The relevant competitive framework is generic drug competition under the ANDA pathway.
What licensing deals affect aminocaproic acid?
No major current licensing transaction is required to commercialize the conventional generic product. Manufacturers typically rely on internal development, contract manufacturing, or acquisition and transfer of approved generic applications.
Licensing value could arise from:
- An approved sterile injectable ANDA.
- A validated plastic-container manufacturing line.
- A regional distribution agreement.
- A supply agreement with a hospital distributor.
- A proprietary container-closure system.
- A co-development arrangement for a new delivery format.
The commercial value of any deal depends more on manufacturing reliability, active customer contracts, and regulatory history than on the underlying aminocaproic acid molecule.
What are the main risks for a generic launch?
A new entrant would face regulatory and operational execution risk rather than composition-of-matter patent risk.
Key launch requirements include:
- FDA-approved application or ANDA.
- Demonstrated injectable product quality.
- Validated sterility and aseptic process.
- Container-closure integrity.
- Extractables and leachables assessment.
- Stability data for the marketed plastic container.
- Reliable active pharmaceutical ingredient supply.
- Hospital distribution and stocking strategy.
- Competitive contracting with group purchasing organizations.
- Adequate pharmacovigilance and recall readiness.
A generic launch can succeed with modest volume if the supplier differentiates through consistent availability, competitive procurement terms, and reliable packaging. A low-price strategy without dependable supply is less durable in sterile injectables.
Key Takeaways
- Aminocaproic acid injection in plastic containers is a mature FDA-approved generic product.
- The active ingredient has no meaningful remaining composition-of-matter exclusivity.
- Clinical use persists in selected surgical, hematology, mucosal, urologic, and emergency settings.
- Tranexamic acid is the principal therapeutic competitor and has stronger modern evidence in trauma and postpartum hemorrhage.
- No biosimilar pathway applies.
- Paragraph IV litigation and patent-settlement risk are limited for conventional presentations.
- Packaging, sterility, container compatibility, and manufacturing reliability are more important than broad patent protection.
- The 2025-2030 market outlook is stable to modestly declining in units, with revenue volatility caused by shortages and supplier exits.
- The base-case indexed market projection declines from 100 in 2025 to 95 in 2030.
- Commercial diligence should focus on active FDA listings, supplier count, shortage history, hospital contracts, and Orange Book status by presentation.
Frequently Asked Questions
Is aminocaproic acid injection still FDA approved?
Yes. Aminocaproic acid injection is an established FDA-approved prescription product, with generic versions marketed through approved abbreviated new drug applications.
Is aminocaproic acid injection interchangeable with tranexamic acid?
No. The drugs have related antifibrinolytic mechanisms but different dosing, evidence bases, labeling, and institutional protocols. Substitution requires clinical authorization.
Does a plastic container create separate patent protection?
Usually not. The container may be covered by narrow packaging, compatibility, or manufacturing claims, but the packaging does not restore exclusivity for the active ingredient.
Is aminocaproic acid used for postpartum hemorrhage?
It may be used in selected settings, but tranexamic acid has the stronger contemporary evidence base and broader guideline visibility for postpartum hemorrhage.
What is the biggest commercial threat to aminocaproic acid injection?
Therapeutic substitution by tranexamic acid is the principal long-term threat. Short-term revenue risk is more often driven by generic price competition, hospital contracting, manufacturing interruptions, and product shortages.
References
- U.S. Food and Drug Administration. (n.d.). Aminocaproic acid injection prescribing information. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
- CRASH-2 Collaborators. (2010). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage: A randomised, placebo-controlled trial. The Lancet, 376(9734), 23-32.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
- U.S. Food and Drug Administration. (n.d.). Current good manufacturing practice for finished pharmaceuticals, 21 C.F.R. Parts 210-211. FDA.
